Education
About Us
Working with TipRanks
Follow Us
Icon plc (ICLR)
NASDAQ:ICLR
ICLR Stock Chart & Stats
$185.87
-$3.85(-1.73%)
At close: 4:00 PM EST
$185.87
-$3.85(-1.73%)
Day’s Range― - ―
52-Week Range$125.10 - $228.29
Previous CloseN/A
Volume330.38K
Average Volume (3M)922.10K
Market Cap
$14.19B
Enterprise Value$16.77B
Total Cash (Recent Filing)$468.89M
Total Debt (Recent Filing)$3.57B
Price to Earnings (P/E)25.1
Beta1.00
Next Earnings
Feb 25, 2026EPS Estimate
3.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.31
Shares Outstanding76,359,930
10 Day Avg. Volume1,038,877
30 Day Avg. Volume922,095
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)1.82
Price to Sales (P/S)2.09
P/FCF Ratio15.46
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue2.07
Enterprise Value/Gross Profit7.71
Enterprise Value/Ebitda14.22
Forecast
1Y Price Target
$204.80Price Target Upside10.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)13.08
Revenue Forecast (FY)$8.07B
Bulls Say, Bears Say
Bulls Say
Leadership TransitionBarry Balfe has been settling into his new position as CEO nicely, allowing for a smooth transition due to his critical role and relationships with large Pharma as COO.
Market RecoveryThe company believes it has had good gross bookings as the market recovers, highlighting its strong competitive position and suggesting recent headwinds are transient.
Strategic PartnershipsICON is a global CRO that should benefit from its strategic partnerships with large pharma and growing exposure in the faster-growing biopharma end-market.
Bears Say
Cancellations ImpactICON is continuing to work through cancellations, which will have an impact on revenue in the near term.
Macro And Idiosyncratic HeadwindsMacro and ongoing idiosyncratic headwinds are likely to persist over the next 2-3 quarters, weighing on its performance.
Margin PressureManagement expects margin pressure from higher pass-through costs to continue, impacting profitability.
Icon News
ICLR FAQ
What was Icon plc’s price range in the past 12 months?
Icon plc lowest stock price was $125.10 and its highest was $228.28 in the past 12 months.
What is Icon plc’s market cap?
Icon plc’s market cap is $14.19B.
When is Icon plc’s upcoming earnings report date?
Icon plc’s upcoming earnings report date is Feb 25, 2026 which is in 79 days.
How were Icon plc’s earnings last quarter?
Icon plc released its earnings results on Oct 22, 2025. The company reported $3.31 earnings per share for the quarter, beating the consensus estimate of $3.301 by $0.009.
Is Icon plc overvalued?
According to Wall Street analysts Icon plc’s price is currently Undervalued.
Does Icon plc pay dividends?
Icon plc does not currently pay dividends.
What is Icon plc’s EPS estimate?
Icon plc’s EPS estimate is 3.32.
How many shares outstanding does Icon plc have?
Icon plc has 76,359,930 shares outstanding.
What happened to Icon plc’s price movement after its last earnings report?
Icon plc reported an EPS of $3.31 in its last earnings report, beating expectations of $3.301. Following the earnings report the stock price went down -6.542%.
Which hedge fund is a major shareholder of Icon plc?
Currently, no hedge funds are holding shares in ICLR
Icon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$204.80 (10.18% Upside)
$204.80 (10.18% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 216.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.27%
12-Months-Change
Fundamentals
Return on Equity
6.27%
Trailing 12-Months
Asset Growth
-4.09%
Trailing 12-Months
Company Description
Icon plc
ICON plc is a global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990 and headquartered in Dublin, Ireland, ICON specializes in conducting clinical trials and providing consulting services, regulatory affairs, and data management solutions to help clients bring their products to market efficiently. The company operates across various therapeutic areas and boasts a diverse range of services including full-service clinical development, laboratory services, and patient recruitment.
ICLR Company Deck
ICLR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of ICON plc's performance. While there were strong business awards and strategic investments in technology, the company faced challenges with elevated cancellations and pricing pressures affecting margins. The overall outlook remains cautiously optimistic, with expectations of normalized cancellation levels and continued technological advancements.View all ICLR earnings summariesICLR Stock 12 Month Forecast
Average Price Target
$204.80
▲(10.18% Upside)
Technical Analysis
Ownership Overview
0.39% Insiders
30.28% Mutual Funds
27.84% Other Institutional Investors
39.75% Public Companies and
Individual Investors